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Edited by Varda RotterAbstract RB18A (TRAP220/DRIP205) is a cofactor of tran-
scription. We herein demonstrated that RB18A downregulated
p53 and upregulated MDM2 promoters. These RB18A regula-
tions, not modiﬁed by p53wt expression, were inhibited by mu-
tant p53 (p53mut) expression, which directly interacts with
RB18A D5 domain. In addition, RB18A via its D4 domain, also
interacts directly and speciﬁcally with MDM2 protein inhibiting
p53mut degradation. Altogether, these mechanisms contribute to
maintain a high level of p53mut expression in tumor proliferating
cells. Therefore, RB18A plays a central role to control p53wt
and p53mut protein content and functions in cells through a loop
of regulation, which involves MDM2.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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MDM2 promoter1. Introduction
RB18A is a human gene, which encodes a 205 kDa protein
[1]. RB18A was antigenically and functionally related to p53
[1]. Indeed, sequence of RB18A cDNA demonstrated that, de-
spite absence of signiﬁcant homologies between RB18A and
p53 nucleotide sequences, both proteins were recognized by
three diﬀerent anti-p53 monoclonal antibodies (moAb). In vi-
tro and in vivo, RB18A, through its C-terminal domain, di-
rectly interacted with p53wt [1,2]. RB18A is a cofactor of
transcription by diﬀerently regulating p53-transactivating
activity on the promoter of Bax (activated), p21Waf1 and
IGF-BP3 (both inhibited) genes [2]. In absence of p53wt,
RB18A had no regulatory eﬀect on these three promoters. In
addition, RB18A inhibited p53wt-dependent apoptosis [3].
This downregulation of p53wt function was due to upregula-
tion by RB18A of MDM2 protein expression, which promoted
p53wt degradation into proteasome [4], by activating MDM2
promoter, through a p53wt-independent mechanism.
Human RB18A shares 98% nucleic sequence identity, func-
tional properties and identical gene localization with two hu-
man cellular components described later, TRAP220 [5,6] and
DRIP205 [7], both interacting with distinct hormone-activated
nuclear receptors.
Taking into account the above properties of RB18A to reg-
ulate p53wt functions [2,3] and our previous demonstration
that in vitro RB18A also interacted with p53mut [1], we herein*Corresponding author. Fax: +33 1 60 78 29 54.
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doi:10.1016/j.febslet.2005.03.026analyzed whether a functional relationship could also exist in
vivo between RB18A and p53mut.2. Materials and methods
2.1. Cells, plasmids and antibodies
K562 and H1299, both p53 null cell lines, were grown in DMEM
containing 10% SVF, 100 units/ml penicillin–streptomycin. H1299
val135 cells, which stably express p53wt at 32 C or p53mut at
37 C, (kindly provided by Dr. M. Oren, Weizmann Institute, Reho-
vot, Israel) were grown in DMEM supplemented with G418.
The expression vectors were: pCMV-RB18A prepared in our labora-
tory [1] ; pCMV-p53wt and pCMV-MDM2 (kindly provided by
Dr. Bert Vogelstein, John Hopkins University, Baltimore, MD);
pCMV-p53mut143, p53mut175 or p53mut179, with mutation Val/Ala
in position 143, Arg/His in position 175 or His/Gln in position 179,
respectively, devoid of transactivating activity (kindly provided by
Dr. M. Bar-Eli, M. D. Anderson Cancer Center, UT, Houston, USA).
Vectors for transactivation experiments were: Pp53-CAT, p53 pro-
moter (provided by Dr. M. Bar-Eli). pMDM2-NA-Luc, which con-
tained the minimal p53-responsive promoter of MDM2 was
constructed in our laboratory after PCR ampliﬁcation of pMDM2
promoter (provided by Dr. M. Oren) and inserted in pGL3 vector
(Promega). pCMV-b Gal (Clontech) was also used.
Anti-RB18A polyclonal and moAbs were prepared in our labora-
tory [1]. Anti-p53 and anti-MDM2 moAbs were from Oncogene
(MA, USA), anti-GAPDH moAb from Chemicon (CA, USA) and
anti-CD21 moAb from Immunotech (Marseilles, France).
2.2. Transactivation experiments
107 K562 cells were transfected by electroporation and 106 H1299
cells or H1299 val135 were transfected by calcium phosphate coprecip-
itation method, as previously described [2]. pCMV-b-Gal plasmid di-
luted 1/20 or 1/4 for CAT or luciferase assay, respectively, was
added as an internal control for normalization of transfection eﬃ-
ciency. b-gal activity was tested using reporter lysis buﬀer (Promega).
CAT assays, their quantiﬁcation and luciferase assays were performed
as already described [2]. The relative luciferase or CAT activity was
calculated as the ratio of the value obtained for each sample compared
to the promoter alone.
2.3. Immunoprecipitation and immunoblotting
Transfected cells or Raji cells were collected and lysed. Protein con-
tent of solubilized cells was normalized after a BCA assay. Then, 1 mg
protein was submitted to immunoprecipitation assays by incubation
with 5 lg antibodies bound on sepharose protein A/G (Santa Cruz).
After extensive washes of immunobeads, bound proteins were eluted
in sample buﬀer and analyzed by SDS–PAGE. Immunoblotting was
performed using indicated polyclonal or moAbs, followed by incuba-
tion with peroxidase-labeled secondary Ab and detected with ECL
(Pharmacia).2.4. Construction of recombinant domains of RB18A
PCR samples containing 500 ng pCMV-RB18A were heated for
5 min at 94 C, then submitted to 30 cycles of 1 min at 94 C, 1 min
at 55 C, 1.30 min at 72 C, with a ﬁnal extension of 7 min at 72 C.blished by Elsevier B.V. All rights reserved.
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the diﬀerent domains of RB18A (see Fig. 4). After puriﬁcation, PCR
fragments corrresponding to RB18A domains were ligated into PGEX
vector (Amersham, France). After sequencing the inserts, fusion pro-
teins were produced in BL21 bacteria.
2.5. In vitro binding assay
Recombinant GST fusion proteins (5 lg) were bound to glutathione-
Sepharose 4B beads (Amersham, France) for 1 h at 4 C, then incu-
bated for 2 h at 4 C with 500 lg proteins solubilized from Raji cells.
After incubation, beads were washed ﬁve times with lysis buﬀer. Bound
proteins were eluted, submitted to SDS–PAGE, then analyzed by
immunoblotting using the indicated Abs.3. Results and discussion
First, we analyzed whether RB18A regulates p53 promoter.
Thus, H1299 cells, a p53 negative cell line, were co-transfected
with p53 promoter cloned upstream CAT gene and with
RB18A in absence or in presence of p53wt or each three mu-
tants p53 (p53mut), all devoid of transactivating activity, i.e.,
p53mut143 (Val/Ala), p53mut175 (Arg/His) or p53mut179
(His/Gln) [8]. The optimal concentrations and ratio of
RB18A, p53wt or p53mut forms were determined in prelimin-
ary experiments, using various concentrations of each compo-
nent. In Fig. 1, p53 promoter activity (lane 1), known to be
constitutively activated [9], was totally inhibited by p53wt
(lane 2) and only partially (by 30%) by p53mut143 (lane 3a),Fig. 1. RB18A regulates p53 promoter activity. 106 H1299 p53 null
cells were transfected by calcium phosphate coprecipitation method,
with 2.5 lg pp53-CAT, p53 promoter (lanes 1–6). Some of them were
co-transfected with 6 lg pCMV-p53wt (lanes 2 and 5) or 6 lg pCMV-
p53mut143 (lanes 3a and 6a), pCMV-p53mut175 (lanes 3b and 6b) or
pCMV-p53mut179 (lanes 3c and 6c), in absence (lanes 2, 3a, 3b and 3c)
or in presence (lanes 4, 6a, 6b and 6c) of 6 lg pCMV-RB18A. Pp53-
CAT was analyzed on TLC (A) and quantiﬁed by LSC (B), as
previously described [3]. This experiment is representative of ﬁve
diﬀerent experiments.p53mut175 (lane 3b) or p53mut179 (lane 3c). In absence of
p53wt or p53mut, RB18A inhibited up to 70% p53 promoter
activity (lane 4). In addition, cells were co-transfected with
RB18A and p53wt or each three p53mut forms. Data demon-
strated that RB18A inhibitory eﬀect on p53 promoter activity
was not signiﬁcantly modiﬁed in presence of p53wt (lane 5),
while totally inhibited in presence of mutant p53 forms, i.e.,
p53mut143 (lane 6a), p53mut175 (lane 6b) or p53mut179 (lane
6c, as compared to the control (lane 1). Furthermore, as we
previously demonstrated that RB18A also regulated MDM2
promoter in p53wt-independent mechanism [3], we analyzed
the eﬀect of the expression of the three mutants p53 on this
RB18A regulatory function. H1299 cells were co-transfected
with MDM2 promoter cloned upstream Luc gene and with
p53wt or each p53mut in absence or in presence of RB18A.
In Fig. 2, MDM2 promoter, constitutively inactive (lane 1),
was activated by p53wt (lane 2) but not by p53mut143 (lane
3a), p53mut175 (lane 3b) or p53mut179 (lane 3c). In control,
RB18A alone activated MDM2 promoter activity (lane 4), at
the same maximum level induced by p53wt alone (lane 2). This
RB18A regulatory function on MDM2 promoter was not
modiﬁed by p53wt expression (lane 5). However, this RB18A
regulatory function was totally inhibited by p53mut143 (lane
6a), p53mut175 (lane 6b) or p53mut179 (lane 6c) expression.
These data demonstrated that mutant p53 forms totally inhibit
the regulatory function of RB18A on p53 promoter (i.e., inhi-
bition) and on MDM2 promoter (i.e., activation).
This full inhibition of RB18A regulatory functions led us to
analyze whether RB18A expression also modiﬁed the cell con-
tent of ectopic p53mut protein (Fig. 3). Thus, the expression of
p53mut143, p53mut175 or p53mut179 was analyzed in H1299
cells co-transfected with cDNA coding for RB18A,
p53mut143, p53mut175, p53mut179 or MDM2 proteins, as de-
scribed above. As identical results were obtained using the
three mutant p53 forms, we herein presents data obtained with
p53mut145. Co-transfection of p53mut and RB18A led to a
signiﬁcant 30% increase in p53mut content (Part A1, lane 2),
when compared to p53mut transfected alone (lane 1). Co-
transfection of MDM2 and p53mut decreased by 50%Fig. 2. RB18A regulates MDM2 promoter activity. 106 H1299 cells
were transfected with 1 lg pMDM2-NA-Luc, the minimal p53-
responsive promoter of MDM2 (lanes 1–6). Some of them were
co-transfected with 0.1 lg pCMV-p53wt (lanes 2 and 5), 0.1 lg pCMV-
p53mut143 (lanes 3a and 6a), pCMV-p53mut175 (lanes 3b and 6b) or
pCMV-p53mut179 (lanes 3c and 6c). In absence (lanes 2, 3a, 3b and
3c) or in presence (lanes 4, 6a, 6b and 6c) of 0.4 lg pCMV-RB18A.
Each transactivating experiment was performed at least ﬁve times.
Fig. 3. RB18A eﬀect on ectopic and endogenous p53mut and MDM2
expression. Part A: 106 H1299 cells were transfected with 3 lg pCMV-
p53mut (lanes 1–5) or with 3 lg pCMV-MDM2 (lanes 3–5), in absence
(lanes 1, 3 and 5) or in presence (lanes 2 and 4) of 6 lg pCMV-RB18A.
In lane 5, cells were pretreated for 2 h with 100 lMMG-132, a speciﬁc
proteasome inhibitor [3]. Part B: 106 H1299 val135 cells, which stably
express p53mut at 37 C or p53wt at 32 C, were transfected for 22 h
with 6 lg pCMV (lanes 1 and 3) or with pCMV-RB18A (lanes 2 and
4), then maintained for 24 h at 37 C (lanes 1 and 2) or at 32 C (lanes 3
and 4). Then, 50 lg solubilized proteins were submitted on SDS–
PAGE and immunoelectrotransferred. Immunodetections were per-
formed with 0.5 lg/ml anti-p53 moAb. (Parts A1 and B2), 1 lg/ml
anti-MDM2 moAb (Parts A2 and B1) or anti-GAPDH moAb diluted
1/40,000 (Parts A3 and B3). This ﬁgure is representative of ﬁve
diﬀerent experiments.
Fig. 4. ‘‘In vivo ‘‘ and ‘‘In vitro’’ interaction of RB18A with MDM2.
On Part A: Proteins solubilized from Raji cells were submitted on
SDS–PAGE either directly (lanes 1) or after immunoprecipitation on
immobilized polyclonal anti-RB18A Ab (lanes 2–3) or anti-CD21 (lane
4), anti-MDM2 (lane 5) or anti-p53 (lane 6) moAbs of either from total
cell extract (lanes 3–6) or from eﬄuents of cell extract absorbed 4 times
on anti-RB18A immunobeads (lanes 2). Immunodetection was per-
formed as previously described [3], with anti-RB18A (Part A1), anti-
MDM2 (Part A2) or anti-p53 (Part A3) moAbs. On Part B: In Part B1,
schematic representation of RB18A D1 to D5 domains constructed by
PCR and puriﬁed as described. In Part B2, recombinant GST fusion
proteins (5 lg) were incubated with 500 lg proteins solubilized from
Raji cells. After SDS–PAGE and immunoelectrotransfer, bound
proteins were detected using anti-MDM2 and anti-p53 moAbs.
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thermore, when RB18A was co-transfected with MDM2 and
p53mut (lane 4), expression of p53mut was increased ﬁve times
(as compared to lane 3). The same high level of p53mut was
measured in cells pretreated with MG-132, a proteasome
inhibitor and co-transfected only with p53mut and MDM2
(lane 5). In addition, when cells were co-transfected with
p53mut and MDM2, all driven by pCMV, the level of ectopic
MDM2, while higher, remained almost unchanged in absence
of RB18A, without (lane 3) or with MG-132 pretreatment
(lane 5), or in presence of RB18A (lane 4). As control, endog-
enous GAPDH amount was identical in all samples (Part A3,
lanes 1–5). These results supported that p53mut protein degra-
dation by MDM2 (lane 3) was prevented by RB18A expression
(lane 4), as well as MG-132 pretreatment (lane 5). In addition,
as in the above experiments the diﬀerent constructs were driven
by CMV promoter, it was needed to analyze the regulatory
functions of RB18A expression on endogenous p53wt or
p53mut and MDM2. For this purpose, H1299 val135 cells
were used (Part B). These cells were stably transfected with a
temperature sensitive p53, i.e., p53mut at 37 C (lanes 1 and
2) or p53wt at 32 C (lanes 3 and 4) [11]. Data demonstratedthat at 37 C, RB18A expression increased p53mut level
(lane 2, Part B2) and decreased MDM2 level (lane 2, Part
B1), while at 32 C, RB18A expression decreased p53wt level
(lane 4, Part B2) and enhanced MDM2 expression (lane 4, Part
B1). This variation in MDM2 expression is in good agreement
with the RB18A regulatory function on MDM2 promoter [3]
and with the p53 type expressed. Altogether, these data dem-
onstrate that RB18A expression has divergent eﬀects on the
cellular levels of both p53 and MDM2 proteins, depending
on the conformational state (mutant or wild-type) of p53. In
addition, when transfected with RB18A, the proliferation level
at 37 C of temperature sensitive cells (which expressed
p53mut at 37 C) or of Raji cells (which expressed endogenous
p53mut [12]), increased by up to 30% (data not shown). Thus,
these data clearly support the biological outcome of RB18A
ectopic expression on endogenous p53mut and MDM2.
This increase in p53mut cell content induced in presence of
both RB18A and MDM2 led us to verify whether in vivo
RB18A interacted directly with MDM2. Therefore, cell ex-
tracts prepared from Raji cells, which express endogenous
RB18A, MDM2 and p53mut [12], were submitted to immuno-
precipitation assays using the indicated speciﬁc antibodies
(Fig. 4, Part A). Then, immunoprecipitated proteins were de-
tected by immunoblotting using either anti-RB18A (Part
A1), anti-MDM2 (Part A2) or anti-p53 (Part A3) moAbs,
respectively. Data demonstrated that MDM2 protein (Part
A2, lane 3) and p53mut protein (Part A3, lane 3) co-precipi-
tated with RB18A (Part A1, lane 3). Conversely, RB18A (Part
A1, lane 5) and p53mut (Part A3, lane 5). co-precipitated with
MDM2 (Part A2, lane 5) In addition, MDM2 (Part A2, lane 6)
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(Part A3, lane 6). In absence (lanes 2 and 4) of RB18A protein
(Part A1), neither MDM2 (Part A2) nor p53mut (Part A3)
proteins were immunoprecipitated, as controlled using either
polyclonal RB18A Ab on cellular extracts depleted in
RB18A protein (lanes 2) or irrelevant antibody, anti-CD21
moAb, on total cell extracts (lanes 4). Then, the speciﬁcity of
MDM2 interaction with RB18A was analyzed using fusion
proteins corresponding to ﬁve domains, named D1 to D5, of
RB18A (Part B). These ﬁve domains were constructed with
similar apparent molecular weights, with the two LXXLL se-
quences [5] on separate domains (one on D2 and the other
on D3) and with the p53-binding domain on D5 [1] (Fig. 4,
Part B1). These D1 to D5 fusion proteins were incubated with
Raji cell extracts in pull-down assays and associated proteins
were detected using anti-p53 and anti-MDM2 moAb (Fig. 4,
Part B2). Thus, MDM2 protein speciﬁcally interacted with
D4 domain (amino acids 893 to 1229) of RB18A and not with
other four domains (D1, D2, D3 or D5). p53mut interacted
only with D5 domain, the carboxy-terminal domain on which
p53wt also bound [1]. Therefore, RB18A, by interacting
through its D4 domain with MDM2, prevents p53mut degra-
dation triggered by MDM2. Further studies are needed to
determine the mechanism of this inhibition.
In conclusion, from our previous data [3] and those herein
presented, RB18A plays a central role to control p53wt and
p53mut protein content and functions in cells through a loop
of regulation, which involves MDM2. Indeed, in human cells
which express p53wt, RB18A: (1) regulates p53wt transcrip-
tional activity on physiological promoters [2]; (2) diminishes
p53wt-dependent apoptosis by promoting p53wt degradation
into the proteasome via MDM2, whose expression is upregu-
lated by RB18A [3]. In human cells, which express p53mut:
(1) p53mut, by interacting with RB18A D5 domain, inhibits
upregulation of MDM2 promoter activity or downregulation
of p53 promoter activity by RB18A; (2) RB18A via its D4 do-
main, interacts directly and speciﬁcally with MDM2 protein
inhibiting p53mut degradation. Thus, these mechanisms con-
tribute to maintain the p53mut expression at high level in tu-
mor proliferating cells.Acknowledgments: This work was supported by INSERM, Fondation
de France (Comite´ sur Leuce´mies) and Association de Recherches con-
tre le Cancer (ARC, Villejuif).
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